Longitude Cayman Ltd. Has $786,000 Holdings in Amarin Co. plc (NASDAQ:AMRN)

Longitude Cayman Ltd. decreased its stake in shares of Amarin Co. plc (NASDAQ:AMRN - Free Report) by 31.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,620,000 shares of the biopharmaceutical company's stock after selling 750,000 shares during the quarter. Longitude Cayman Ltd. owned 0.39% of Amarin worth $786,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in AMRN. China Universal Asset Management Co. Ltd. raised its position in Amarin by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company's stock worth $48,000 after purchasing an additional 29,992 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Amarin by 8.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company's stock worth $816,000 after buying an additional 104,939 shares during the period. Arkfeld Wealth Strategies L.L.C. lifted its position in shares of Amarin by 52.6% during the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 20,000 shares during the period. LCM Capital Management Inc boosted its stake in Amarin by 3.1% in the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock valued at $407,000 after buying an additional 25,100 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its stake in Amarin by 80.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 42,700 shares in the last quarter. Institutional investors own 22.25% of the company's stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Amarin from a "sell" rating to a "hold" rating in a report on Tuesday.

Amarin Stock Up 1.2 %

AMRN stock traded up $0.01 during midday trading on Friday, reaching $0.61. 922,387 shares of the company's stock traded hands, compared to its average volume of 1,168,729. The company has a 50-day simple moving average of $0.53 and a two-hundred day simple moving average of $0.57. Amarin Co. plc has a 1-year low of $0.43 and a 1-year high of $1.36. The company has a market cap of $251.49 million, a price-to-earnings ratio of -6.80 and a beta of 1.83.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.